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EDITORIALRecurrent ovarian cancer in the era of poly-ADP ribose polymerase
inhibitors: time to re-assess established clinical practicesAs oncologists reflecting on the past 20 years of medical
oncology, we recognize many therapeutic advances that
have changed our practice and, above all, saved patients’
lives. For epithelial ovarian cancer (EOC), the introduction of
poly-ADP ribose polymerase inhibitors (PARPi) is one such
historic achievement, comparable with the implementation
of anti-human epidermal growth factor receptor 2 (HER2)
antibodies for the treatment of HER2-positive breast cancer.
The PARPi revolution started in the setting of recurrent
EOC, when three moleculesdolaparib, niraparib and ruca-
parib administered as maintenance therapyddemonstrated
remarkable effectiveness in prolonging time to progression
in platinum-responsive patients.1-4 Carriers of BRCA1 or
BRCA2 mutations benefitted the most from PARPi. In
particular, olaparib provided a clinically meaningful gain in
survival over placebo in patients with recurrent EOC and a
somatic or germline mutation in BRCA genes.5 In these
studies, a response to platinum-based chemotherapy was
the main requisite to receive PARPi maintenance therapy.
Given their effectiveness as second and further lines of
therapy, PARPi were tested up front after response to plat-
inum therapy. Olaparib was the first PARPi to demonstrate a
clear benefit by prolonging time to recurrence in BRCA1/2-
mutated EOC patients, according to the SOLO1 trial.6
Moreover, olaparib showed effectiveness in association
with bevacizumab for the first-line treatment of EOC with a
homologous recombination deficiency (HRD), defined as a
tumor harboring a BRCA mutation or an HRD score of 42 or
higher on the myChoice HRD Plus assay (Myriad Genetic
Laboratories, Salt Lake City, UT).7 Finally, niraparib has been
approved by both the US Food and Drug Administration and
the Europen Medicines Agency for newly diagnosed EOC
irrespective of BRCA mutation status, broadening the spec-
trum of patients who can receive a PARPi after diagnosis.8,9
In the upcoming months, as we scrutinize the data from
the reported trials, we will discuss the impact of first-line
PARPi maintenance therapy on overall survival. Mean-
while, in daily practice we are facing an increasing number
of EOC patients in progression after PARPi. Management of
these patients is currently at the focus of attention, for both
clinicians and researchers, since they seem to benefit less
than expected from platinum-based therapy, with first
preliminary evidences from second-line studies supporting a
possible cross-resistance between PARPi and platinum
agents.2059-7029/© 2021 The Author(s). Published by Elsevier Ltd on behalf of
European Society for Medical Oncology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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particular to platinum salts. In fact, the period between the
last platinum dose and the evidence of relapsing disease,
the so-called platinum-free interval (PFI), has been widely
used as a surrogate of platinum sensitivity to guide suc-
cessive treatment choices. For patients with a PFI 6
months (i.e. disease recurrence 6 or more months after the
last platinum dose), platinum-based chemotherapy is used
to be rechallenged again. Despite the fact that the clinical
utility of PFI has been previously questioned and integrated
within the concept of treatment-free interval since the
introduction of maintenance strategies,10 we should
recognize that its use in clinics has never been abandoned.
One explanation for the continued use of PFI is its ability to
predict benefit from a rechallenge with platinum, even in
patients undergoing maintenance therapy with bev-
acizumab. This evidence comes from the MITO 16b trial of
second-line platinum therapy plus bevacizumab beyond
progression that has been recently published in the Lancet
Oncology.11 The study found that the effectiveness of
platinum chemotherapy, with or without bevacizumab,
seems to not have been affected by the previous anti-
angiogenic therapy. Moreover, the benefit of bevacizumab
on progression-free survival was similar to that reported in
the OCEANS trial, which excluded patients who had previ-
ously been treated with bevacizumab.12
Our own clinical experience and initial observations
reported in the literature suggest that BRCA-mutated tu-
mors progressing during PARPi may have cross-resistance to
platinum. For this reason, we question the usefulness of the
PFI in this clinical setting. Recently, at the 2020 annual
meeting of the European Society for Medical Oncology, a
secondary analysis of post-progression outcomes of pa-
tients in the SOLO2 trial was presented. With major limi-
tations due to the unbalance between the two treatment’s
arms at olaparib/placebo progression, patients in the pla-
cebo arm seemed to benefit the most from a rechallenge
with platinum, while those who received olaparib did
worse, with median times to second progression of about
14 months versus 7 months, respectively.13 These findings
are in accordance with our MITO retrospective study of 234
patients with BRCA1/2-mutated recurrent EOC receiving
olaparib as for clinical practice.14 The study found a lower
than expected response rate to subsequent platinum ther-
apy that, in patients with a PFI >12 months at the time of
recurrence to olaparib, was only about 22%. A similar
finding has been presented by Baert et al.15 in a mixed
population of patients treated with olaparib and niraparib1
ESMO Open Editorialwho showed a low response to subsequent platinum when
compared with matched PARPi naive controls.
From a biological point of view, the molecular drivers of
resistance to PARPi are not fully known, but are thought to
involve the restoration of homologous recombination pro-
ficiency through reverse mutations in BRCA1, RAD51C or
RAD51D, demethylation of the BRCA1 promoter and over-
expression of ABCB1, which encodes a transmembrane drug
exporter.16 Moreover, PARPi and platinum agents share
several mechanisms of resistance that can explain the cross-
resistance to the two drugs.
Given the emerging evidence that PFI is unable to predict
benefit from additional platinum therapy, at least in pa-
tients with BRCA-mutated recurrent EOC progressing during
PARPi, future studies aimed to test new agents that could
be able to overcome cross-resistance mechanisms are
needed, especially in the recurrent setting where patients
receive PARPi until disease progression developing a
possible ‘primary resistance’.
By contrast, in patients receiving PARPi after first-line
platinum therapy, disease recurrence can be detected af-
ter the completion of the 24 or 36 months of PARPi adju-
vant therapy and they could continue to benefit from
platinum and PARPi in a sort of ‘secondary resistance’; this
issue is currently under investigation in the OReO trial
(NCT03106987).
Waiting for the results of new investigational drugs, the
treatment options yet available should be reassessed in the
recurrent setting in order to define the best treatment
sequence. It appears useful to re-test if the addition of
bevacizumab can enhance the platinum performance, as
previously demonstrated in PARPi-naive patients.12,17,18 New
studies should also analyze whether non-platinum-based
chemotherapy, such as trabectedin combined with the
pegylated liposomal doxorubicin, performs better than
platinum-based chemotherapy, a possibility considering their
different mechanisms of action on tumor cells.19 Finally, a
secondary tumor debulking could theoretically reduce the
amount of drug-resistant tumor cells, improving the effec-
tiveness of subsequent treatments. Thus, the importance of
secondary cytoreductive surgery that should be considered a
standard of care in platinum-sensitive recurrent EOC after
the DESKTOP III and the SOC-1 trials20,21 could be further
reinforced in the post-PARPi scenario, in particular for those
patients receiving PARPi in a first-line setting and who
experience a recurrence after the end of therapy. Although
reasonable, this hypothesis needs a prospective validation.
In conclusion, we believe that many of the ground-
breaking achievements in the treatment of EOC that we
considered established, in particular the use of PFI, the
options of platinum and non-platinum therapy for recurrent
disease, and the addition of bevacizumab to improve the
activity of platinum-based chemotherapy, need to be re-
assessed for patients previously treated with PARPi.
Further secondary analyses of post-progression outcomes
from the pivotal PARPi trials could identify new predictive
factors of platinum benefit other than PFI; these analyses
should be encouraged as they are hypotheses generating2
for future trials. Furthermore, more data on post-
progression outcomes for BRCA wild-type patients in pro-
gression to PARPi are needed, since these patients are
considered less chemosensitive compared with the BRCA-
mutated counterpart and thus the benefit of post-
progression therapies could be even worse.
Hopefully, novel treatment combinations that could
overcome resistance to PARPi and platinum salts are under
investigation and they could fulfill the unmet clinical need
in this setting. In particular, small molecules targeting
checkpoint proteins activated in response to replication
stress, like ATR, CHK1 and WEE1, can have a synergistic
activity with PARPi, as they could overcome key mecha-
nisms of PARPi resistance while PARP inhibition sensitizes
to ATR/CHK1/WEE1 inhibition.22 Even the combination of
PARPi with PI3K inhibitors has shown a synergistic activity in
patients with de novo or acquired HR proficient EOC, and
the association of olaparib plus alpelisib, a selective a-
specific PI3K inhibitor, is under evaluation in a randomized
phase III trial (NCT04729387).
Preclinical studies will also play a crucial role in our un-
derstanding of the mechanisms of PARPi resistance, and the
inclusion of translational research in future clinical trials will
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